InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $8.60.

Several research firms recently commented on IFRX. Guggenheim raised their target price on InflaRx from $10.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wall Street Zen downgraded shares of InflaRx from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Monday. Finally, HC Wainwright began coverage on shares of InflaRx in a report on Tuesday, September 2nd. They issued a “buy” rating and a $6.00 price target for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC acquired a new stake in InflaRx in the second quarter valued at approximately $65,000. DAFNA Capital Management LLC bought a new position in shares of InflaRx in the 1st quarter worth $459,000. 683 Capital Management LLC grew its position in InflaRx by 26.8% in the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares during the period. XTX Topco Ltd bought a new stake in InflaRx during the 1st quarter valued at $38,000. Finally, Cubist Systematic Strategies LLC increased its stake in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares in the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Stock Performance

IFRX stock opened at $1.18 on Friday. InflaRx has a 52-week low of $0.71 and a 52-week high of $2.82. The company has a market capitalization of $79.22 million, a P/E ratio of -1.47 and a beta of 1.38. The company has a fifty day moving average price of $1.34 and a 200-day moving average price of $1.17.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Monday, November 10th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. As a group, sell-side analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.